Institutional Registry of Rare Diseases

NCT ID: NCT06573723

Last Updated: 2026-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

380 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2034-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).

Moreover, the specific goals are to generate an alert system for possible cases of RD with data from the electronic medical record, to describe the occurrence of RD in the evaluated population, to characterize the population, to describe patterns of diagnosis and treatment of RD present at the time, and to explore patient-reported outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rare Diseases (RD) pose a health challenge due to their complexity and low prevalence, generating a burden in terms of morbidity and mortality and costs.

The fragmentation of data on these diseases makes it difficult to understand them comprehensively. Therefore, the creation of a macro institutional registry that brings together information on RD would facilitate research in this field.

The registries are organized systems of systematic data collection of a large number of patients quickly and efficiently on a particular disease at a given time.

The main difficulty of the registries is the guarantee of the quality of their data.

The main objectives of the registry are:

Understand risk factors and prognosis. Evaluate the diagnostic and therapeutic comparison with current standards. Advance knowledge of the disease to optimize the assessment, treatment and monitoring of patients.

Analyze the effectiveness of new therapies. Studying differences between populations. Quickly estimate the morbidity, mortality and resource utilization associated with a disease entity.

Examine the course of a disease Formulate novel hypotheses for further prospective studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rare Diseases Amyloidosis Sarcoidosis Phacomatosis Pheochromocytoma Paraganglioma Von Hippel-Lindau Disease Immunoglobulin G4-Related Disease Demyelinating Diseases Inborn Errors of Metabolism Eosinophilic Gastrointestinal Disorders Hypertrophic Cardiomyopathy Gaucher Disease Congenital Adrenal Hyperplasia Hereditary Angioedema Pulmonary Hypertension Wilson Disease Vascular Anomalies Mastocytosis Multiple Endocrine Neoplasia Inflammatory Bowel Diseases Prader-Willi Syndrome Hirschsprung Disease Cushing Syndrome HHT Hemorrhagic Hereditary Telangiectasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical and/or molecular diagnosis of any of the following rare diseases: Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, or Cushing Syndrome.
* Must be followed at Hospital Italiano de Buenos Aires.

Exclusion Criteria

\- Refusal to participate in the study or in the informed consent process.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Italiano de Buenos Aires

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

MARIA LOURDES POSADAS MARTINEZ

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marcelo Serra, PhD

Role: PRINCIPAL_INVESTIGATOR

HIBA

Soledad Kleppe, MD

Role: PRINCIPAL_INVESTIGATOR

HIBA

Maria Lourdes Posadas Martinez, PhD

Role: PRINCIPAL_INVESTIGATOR

HIBA

Luis Mazzuoccolo, MD

Role: STUDY_CHAIR

HIBA - dermatología

María Fabiana Russo Picasso, MD

Role: STUDY_CHAIR

HIBA - endocrinología

Eduardo Jorge Premoli, MD

Role: STUDY_CHAIR

HIBA - oftalmología

Mariano Martín Marcolongo, MD

Role: STUDY_CHAIR

HIBA - gastroenterología

Javier Pollan, MD

Role: STUDY_CHAIR

HIBA - clínica médica

Adrian Gadano, MD

Role: STUDY_CHAIR

HIBA - investigación

Pablo Lobos, MD

Role: STUDY_CHAIR

HIBA - cirugía pediátrica

Hernan Garcia Rivello, MD

Role: STUDY_CHAIR

HIBA - patología clínica

Marcelo Risk, PhD

Role: STUDY_CHAIR

IMTIB

Marcelo Rugiero, MD

Role: STUDY_CHAIR

HIBA - neurología

Julio Busaniche, MD

Role: STUDY_CHAIR

HIBA - clínica pediátrica

Rodolfo Pizarro, MD

Role: STUDY_CHAIR

HIBA - cardiología

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Italiano de Buenos Aires

Buenos Aires, Buenos Aires, Argentina

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Argentina

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maria Lourdes Posadas Martinez, PhD

Role: CONTACT

+54 11 49590200 ext. 4419

Paula Scibona, MD

Role: CONTACT

+54 11 49590200 ext. 8425

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ana Braslavsky, MD

Role: primary

+54 11 49590200 ext. 4419

Maria Lourdes Posadas Martinez, PhD

Role: backup

+54 11 49590200 ext. 4419

References

Explore related publications, articles, or registry entries linked to this study.

Griggs RC, Batshaw M, Dunkle M, Gopal-Srivastava R, Kaye E, Krischer J, Nguyen T, Paulus K, Merkel PA; Rare Diseases Clinical Research Network. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009 Jan;96(1):20-6. doi: 10.1016/j.ymgme.2008.10.003. Epub 2008 Nov 13.

Reference Type BACKGROUND
PMID: 19013090 (View on PubMed)

Stoller JK. The Challenge of Rare Diseases. Chest. 2018 Jun;153(6):1309-1314. doi: 10.1016/j.chest.2017.12.018. Epub 2018 Jan 8.

Reference Type BACKGROUND
PMID: 29325986 (View on PubMed)

Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for Evaluating Patient Outcomes: A User's Guide [Internet]. 3rd edition. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Apr. Report No.: 13(14)-EHC111. Available from http://www.ncbi.nlm.nih.gov/books/NBK208616/

Reference Type BACKGROUND
PMID: 24945055 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12332

Identifier Type: REGISTRY

Identifier Source: secondary_id

7014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ARPKD Database Study
NCT01401998 RECRUITING
Primordial Dwarfism Registry
NCT04569149 RECRUITING